Literature DB >> 24004666

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

Ekaterina Chigrinova1, Andrea Rinaldi, Ivo Kwee, Davide Rossi, Paola M V Rancoita, Jonathan C Strefford, David Oscier, Kostas Stamatopoulos, Theodora Papadaki, Francoise Berger, Ken H Young, Fiona Murray, Richard Rosenquist, Timothy C Greiner, Wing C Chan, Ester M Orlandi, Marco Lucioni, Roberto Marasca, Giorgio Inghirami, Marco Ladetto, Francesco Forconi, Sergio Cogliatti, Hana Votavova, Steven H Swerdlow, Stephan Stilgenbauer, Miguel A Piris, Andras Matolcsy, Dominic Spagnolo, Eugene Nikitin, Alberto Zamò, Valter Gattei, Govind Bhagat, German Ott, Emanuele Zucca, Gianluca Gaidano, Francesco Bertoni.   

Abstract

Richter syndrome (RS) occurs in up to 15% of patients with chronic lymphocytic leukemia (CLL). Although RS, usually represented by the histologic transformation to a diffuse large B-cell lymphoma (DLBCL), is associated with a very poor outcome, especially when clonally related to the preexisting CLL, the mechanisms leading to RS have not been clarified. To better understand the pathogenesis of RS, we analyzed a series of cases including 59 RS, 28 CLL phase of RS, 315 CLL, and 127 de novo DLBCL. RS demonstrated a genomic complexity intermediate between CLL and DLBCL. Cell-cycle deregulation via inactivation of TP53 and of CDKN2A was a main mechanism in the histologic transformation from CLL phase, being present in approximately one half of the cases, and affected the outcome of the RS patients. A second major subgroup was characterized by the presence of trisomy 12 and comprised one third of the cases. Although RS shared some of the lesions seen in de novo DLBCL, its genomic profile was clearly separate. The CLL phase preceding RS had not a generalized increase in genomic complexity compared with untransformed CLL, but it presented clear differences in the frequency of specific genetic lesions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24004666     DOI: 10.1182/blood-2013-03-489518

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  63 in total

1.  Haematological cancer: Richter's transformation in CLL-a distinct lymphoma.

Authors:  Preetesh Jain; Ken H Young
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

Review 2.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 3.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

4.  The efficacy of ibrutinib in the treatment of Richter syndrome.

Authors:  Mazie Tsang; Tait D Shanafelt; Timothy G Call; Wei Ding; Asher Chanan-Khan; Jose F Leis; Grzegorz S Nowakowski; Deborah Bowen; Michael Conte; Susan M Schwager; Susan L Slager; Neil E Kay; Curtis A Hanson; Sameer A Parikh
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

Review 5.  Richter transformation in the era of novel agents.

Authors:  Wei Ding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

6.  Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

Authors:  Pietro Bulian; Riccardo Bomben; Michele Dal Bo; Antonella Zucchetto; Francesca Maria Rossi; Massimo Degan; Federico Pozzo; Tamara Bittolo; Vanessa Bravin; Tiziana D'Agaro; Michaela Cerri; Annalisa Chiarenza; Kari G Chaffee; Adalgisa Condoluci; Giovanni D'Arena; Michele Spina; Francesco Zaja; Gabriele Pozzato; Francesco Di Raimondo; Davide Rossi; Giovanni Del Poeta; Gianluca Gaidano; Tait D Shanafelt; Valter Gattei
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

Review 7.  How and when I do allogeneic transplant in CLL.

Authors:  John G Gribben
Journal:  Blood       Date:  2018-05-11       Impact factor: 22.113

8.  How we treat Richter syndrome.

Authors:  Sameer A Parikh; Neil E Kay; Tait D Shanafelt
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

9.  Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.

Authors:  Fabienne Lucas; Kerry A Rogers; Bonnie K Harrington; Rosa Lapalombella; Alexander Pan; Lianbo Yu; Justin Breitbach; Ralf Bundschuh; Virginia M Goettl; Zachary A Hing; Parviz Kanga; Rose Mantel; Deepa Sampath; Lisa L Smith; Ronni Wasmuth; Danielle K White; Pearlly Yan; John C Byrd; Jennifer A Woyach
Journal:  Clin Cancer Res       Date:  2019-07-11       Impact factor: 12.531

10.  Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.

Authors:  Ilaria Del Giudice; Marilisa Marinelli; Jiguang Wang; Silvia Bonina; Monica Messina; Sabina Chiaretti; Caterina Ilari; Luciana Cafforio; Sara Raponi; Francesca Romana Mauro; Valeria Di Maio; Maria Stefania De Propris; Mauro Nanni; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Anna Guarini; Raul Rabadan; Robin Foà
Journal:  Br J Haematol       Date:  2015-11-24       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.